Emergent BioSolutions (EBS) CFO awarded 72,856 options, withholds 23,650 shares for taxes

Rhea-AI Filing Summary

Emergent BioSolutions EVP and CFO Richard S. Lindahl reported routine equity compensation and related tax withholding. On March 3, he acquired 72,856 employee stock options at an exercise price of $0.00 per share as a grant that vests in three equal installments beginning the day prior to each anniversary of the grant date. On March 5, 23,650 shares of common stock were disposed of at $8.44 per share to cover taxes due on the vesting and settlement of restricted stock units, rather than through an open-market sale. After these transactions, he held 215,367 shares of common stock and 557,346 stock options directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LINDAHL RICHARD S

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	23,650	$8.44	$200K
Grant/Award	Employee Stock Option (Right to buy)	72,856	$0.00	--

Holdings After Transaction: Common Stock — 215,367 shares (Direct); Employee Stock Option (Right to buy) — 557,346 shares (Direct)

Footnotes (1)

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		F		23,650(1)	D	$8.44	215,367	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		72,856		(2)	03/02/2033	Common Stock	72,856	$0	557,346	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Emergent BioSolutions (EBS) CFO Richard Lindahl report?

Richard Lindahl reported an equity award and a tax-related share disposition. He received 72,856 stock options as a grant and had 23,650 common shares withheld to pay taxes on vested restricted stock units, not as an open-market sale.

How many Emergent BioSolutions (EBS) stock options were granted to the CFO?

The CFO was granted 72,856 employee stock options. These options were awarded at an exercise price of $0.00 per share and vest in three equal installments beginning the day prior to each anniversary of the grant date, reflecting standard long-term incentive compensation.

Was the Emergent BioSolutions (EBS) CFO’s share disposal an open-market sale?

No, the 23,650 shares were not sold on the open market. They were withheld to pay taxes related to the vesting and settlement of restricted stock units, meaning the transaction satisfied tax obligations rather than representing a discretionary stock sale.

What Emergent BioSolutions (EBS) holdings does the CFO report after these transactions?

After the reported transactions, the CFO held 215,367 shares of common stock and 557,346 employee stock options directly. These figures reflect his updated direct ownership position following the option grant and the tax-withholding share disposition.

How do the new Emergent BioSolutions (EBS) stock options for the CFO vest?

The 72,856 granted stock options vest in three equal installments. Vesting begins on the day prior to the first anniversary of the grant date, with additional equal portions vesting on the corresponding days before the second and third anniversaries.